Search
for
Sort by
Research 601–630 of 1000+
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- An unusual terminal hair growth on the nose tip associated with gefitinib therapy
- Prevention of erlotinib-induced folliculitis with doxycycline
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- Real-World Ritlecitinib Treatment of Severe Alopecia Areata (AA) in the US: Patient Characteristics and Physician Satisfaction
- Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
- Distribution of SALT Scores with Ritlecitinib Treatment up to 24 months from the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
- Dermatologic adverse events in EGFR-TKIs: A real-world analysis.
- 84 Partial restoration of scalp microbiota in alopecia areata with JAK inhibitors
- Case Report: Repigmentation and complete hair regrowth in an 11-year-old preadolescent with alopecia totalis treated with a JAK inhibitor
- Influencing hair regrowth with EGCG by targeting glycogen synthase kinase-3β activity: a molecular dynamics study
- 061 Selective inhibition of tyrosine kinase 2 prevents and restores interleukin-12-induced hair follicle immune privilege collapse: a novel approach to alopecia areata therapy?
- Integrin-linked kinase inhibition via QLT0267 stops the epithelial outgrowth.
- Targeting noncanonical nuclear factor kappa B signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha
- Role of phosphatidylinositol 3‐kinase signaling pathway in radiation‐induced liver injury
- Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss.
- Progressive alopecia areata during TNF-α inhibition with intralesional corticosteroid failure and subsequent improvement following JAK1 inhibition
- <i>In Vitro</i> and <i>In Vivo</i> Models for the Development of Hair Growth Materials By Regulating the <i>β</i>-Catenin Signaling Pathways
- Integrated miRNA-mRNA analysis reveals regulatory pathways underlying the curly fleece trait in Chinese tan sheep
- 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
- Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata